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ABSTRACT
A radiolabeled protein composition adapted for radia
tion therapy which comprises a radioisotope and a pro
tein material containing about 6 or more percent amino
acids which have a sulfhydryl-containing side chain. A
method for carrying out radiation synovectomy of ar
thritic joints. Rhenium radiolabeled protein microspheres are administered which contain cysteine and
other amino acids. A method for radiolabeling a protein
composition whereby the composition is treated with a
reducing agent capable of reducing disulfides to sulfhydryls prior to radiolabeling.
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FIG 3
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FIG 4
RETENTION OF RADIOACTIVITY AT 96 HOURS
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FIG 6
LEACHING TEST OF Re-186 LABELED MICROSPHERES
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FIG 7
RETENTION OF RADIOACTIVITY AT 24 HOURS
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FIG 8
TISSUE BIODISTRIBUTION AT 24 HOURS
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emits gamma radiation, not the beta radiation which is
lethal to diseased synovial membrane.
Accordingly, a need has existed for an improved
method and materials, including radioisotope carrier,
for use in radiation synovectomy treatment of RA. A
BACKGROUND OF THE INVENTION
has also existed for an improved radioisotope car
This invention relates to radiolabeled protein compo need
rier
for
in research, treatment and diagnosis in the
sitions being adaptable for radiation therapy, diagnosis field of use
nuclear medicine.
and research. The invention also relates to a method of
SUMMARY OF THE INVENTION
using protein microspheres for radiation synovectomy. 10
Among the several objects of the invention, there
It is estimated that 1-3% of the population in the
United States has rheumatoid arthritis (hereinafter RA), fore, are the provision of an improved method for treat
which can cause chronic synovial inflammation and can ing RA which is relatively free of harmful side effects
lead to progressive loss of joint function and significant and the provision of an improved radioactivity carrier
disability. RA has heretofore been treated primarily by 15 which is adaptable for use in a wide variety of diagnos
surgical or chemical synovectomy. Surgical synovec tic, treatment and research applications in the field of
tomy consists of the surgical removal of the inflamed nuclear medicine. Other objects and features of the
lining of the joint (synovium), and in general can be invention will be in part apparent and in part pointed
expected to provide limited periods of symptomatic out hereinafter.
relief. It is technically difficult, however, to completely 20 Briefly, therefore, the invention is directed to a radi
remove the synovium from the joint. Surgical synovec olabeled protein composition adapted for radiation ther
tomy entails risks such as infection, hemorrhage and apy or diagnosis of a mammal which comprises a beta
anesthetic problems. Surgery often requires prolonged radiation emitting radioisotope and a protein material
periods of hospitalization and rehabilitation for recov containing at least 6 molar percent amino acids residues
ery. Surgery is expensive, invasive and is not attractive 25 having a sulfhydryl-containing side chain.
The invention is further directed to a substantially
for repeat treatments. Proposed methods of chemical
synovectomy use osmic acid, cobra venom or other spherical radiolabeled protein microsphere adapted for
agents and often have significant systemic effects such radiation therapy of a mammal comprising a radioiso
tope selected from the group consisting of Re-186, Reas injury to the articular cartilage.
Radiation synovectomy has been proposed, for exam 30 188 and the combination of Re-186 and Re-188, and
ple, by Johnson et al., Absorbed Dose Profiles for Radio protein material containing at least about 25 molar per
nuclides of Frequent use in Radiation Synovectomy, Ar cent cysteine and at least about 25 molar percent amino
thritis and Rheumatism, Vol. 34, No. 12, p. 1521 (Dec. acids having a nitrogen-containing side chain.
The invention is further directed to a substantially
1991), for the treatment of RA and offers a viable alter
native to surgery and chemical synovectomy. Radioiso 35 spherical radiolabeled microsphere adapted for radia
topes are commonly used for research, treatment and tion therapy of a mammal consisting essentially of a
diagnosis in the field of nuclear medicine. Such applica radioisotope selected from the group consisting of Retions include liver, lung, bone and tumor scanning and 186, Re-188 and the combination of Re-186 and Re-188,
radiotherapy. Radiation synovectomy radiotherapy 40 and protein material containing at least about 35 molar
involves delivering a lethal dose of beta radiation to percent lysine and at least about 35 molar percent cyste
ine.
diseased synovial membrane.
The invention is further directed to a method for
Radiation synovectomy has been used in Europe but
certain disadvantages have made it generally unaccept carrying out radiation synovectomy of arthritic joints,
able for use in the United States. Radiation synovec- 45 comprising administering to a mammal affected with an
tomy treatments in Europ>e have employed yttnum-90 arthritic joint substantially spherical microspheres com
radiocolloids which emit beta radiation but do not emit prising a protein material containing cysteine, said mi
gamma radiation. It has therefore not been possible to crospheres being radiolabeled with a beta radiation
track radiation leakage and the spread of radioactivity emitting radioisotope selected from the group consist
within the patient using an external gamma ray detec 50 ing of Re-186, Re-188 and the combination of Re-186
tor. Additionally, prior methods of radiation synovec and Re-188.
tomy often suffer from high radioactivity leakage rates
The invention is further directed to an improvement
of the particulate preparations which serve as carriers in a method for radiolabeling a protein composition
for the radioactivity. Radiation synovectomy treat containing amino acids having a sulfhydryl-containing
ments have therefore lacked the ideal source of radia 55 side chain for use in radiotherapy and diagnosis in mam
tion and the ideal radioactivity carrier.
mals. The improvement comprises contacting the com
Microspheres formed from human serum albumin position with a reducing agent capable of reducing
have been proposed for use as radioactivity carriers in disulfides to sulfhydryls and thereafter radiolabeling the
connection with the use of radioactivity for diagnostic composition.
purposes, e.g., lung scanning, as in Radiopharmaceuti 60 BRIEF DESCRIPTION OF THE DRAWINGS
cals, Soc’y Nuc. Med., p. 282, New York (1980). Specif
FIG. 1 is a schematic of a method for radiolabeling
ically, human serum albumin microspheres have been
radiolabeled with Tc-99m and injected or otherwise protein microspheres.
FIG. 2 is a schematic of a second method for radiola
allowed to enter a mammalian host. A gamma ray de
tector has then been used to image certain areas of the 65 beling protein microspheres.
FIG. 3 is a plot of the radioactivity distribution in the
patient. Microspheres labeled with Tc-99m, however,
are not suitable for radiation therapy, and radiation urine of rabbits tested using the microspheres and
synovectomy treatment for RA in particular; Tc-99m method of the invention.
RADIOLABELED PROTEIN COMPOSITION AND
METHOD FOR RADIATION SYNOVECTOMY
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FIG. 4 is a plot of the radioactivity distribution in Mo-99/Tc-99m generators and consequently can be
rabbits tested using the microspheres and method of the readily generated on-site and provided as a “no carrier
invention.
added” radioisotope. Both Re-186 and Re-188 are
FIG. 5 is a plot of the radioactivity distribution in adaptable to radiolabeling by attachment thereof to
rabbits tested using the microspheres and method of the 5 protein compositions, as described hereinbelow.
invention.
The radiolabeled protein compositions of the inven
FIG. 6 is a plot of the results of leaching tests reflect tion may take various geometric forms including nonu
ing the chemical durability of microspheres of the in niform globules, generally rectangular conformations,
vention.
irregular conformations, or substantially spherical mi
FIG. 7 is a plot of the radioactivity distribution in the 10 crospheres. Substantially spherical microspheres are
urine of rabbits tested using the microspheres and preferred for radiation synovectomy for reasons includ
method of the invention.
ing their being more readily sizable, classifiable, and
FIG. 8 is a plot of the radioactivity distribution in more resistant to fragmentation, than other conforma
rabbits tested using the microspheres and method of the tions. As to sizability, there are ongoing studies and
invention.
15 indications that microspheres of certain narrow size
ranges of diameters such as, for example, 10 to 30 mi
DETAILED DESCRIPTION OF THE
crons, may be most appropriate for synovectomy of a
INVENTION
particular joint. It is advantageous, therefore, to be able
“Protein compositions” as used herein designates to select microspheres from a predetermined range of
both those compositions which comprise albumin and 20 diameters, if it is believed that a certain range of diame
other proteins separated from blood products or other ters, or combination of ranges, is most appropriate for
fluids from a mammal and those compositions which the particular application.
comprise chemically synthesized or microbially manu
Three methods for producing protein microspheres
factured proteins. “Synthetic” as used herein in refer radiolabeled with Re or other radioisotopes are 1) the
ence to proteins and microspheres means produced 25 formation of microspheres from radiolabeled material,
from materials other than human blood products. All 2) incorporation of various radionuclides during the
percentages expressed herein are molar percent unless formation of microspheres and, preferably, 3) attach
otherwise indicated.
ment of radionuclides to preformed protein mir.roIt has been discovered that protein compositions spheres. The preparation of protein microspheres for
radiolabeled with Re-186 or Re-188 are effective for 30 subsequent radiolabeling in accordance with the pre
radiotherapy. In particular it has been discovered that ferred method involves emulsification or formation of a
protein microspheres radiolabeled with Re-188 or Re- suspension of aqueous protein droplets in oil, gelation or
186 are effective for use in the treatment of rheumatoid solidification, by application of heat, of the aqueous
arthritis (RA) by radiation synovectomy. It has also protein droplets into rigid microspheres and separation
been discovered that microspheres comprising proteins 35 and sizing of solidified microspheres. The preparation
having a predetermined minimum concentration of of HSA microspheres in this manner is known in the art
amino acid residues having sulfhydryl-containing side and described in Radiopharmaceuticals, Soc’y Nuc.
chains have advantages over previously known protein Med., pp. 282-83, New York (1980) and in White, Prop
microspheres and other radioactivity carriers used in erties & Manufacturing Techniques o f Human Serum
treatment, diagnosis and research in the field of nuclear 40 Albumin Microsphere, M. S. Cer. Eng. Thesis, U. of
medicine.
Mo.-Rolla, p.1-38 (991). This latter reference, at pages
The composition and method of the invention in 39-61, also describes an alternative method, the drop
volve the use of rhenium as a source of radiation at tube system, suitable for producing protein micro
tached to protein compositions. Re-186 and Re-188 emit spheres of the invention. The method of making the
gamma rays, and therefore provide the advantage of 45 protein microspheres is not in itself critical to the inven
being detectable in the host’s system by detection meth tion. Described below are examples illustrating specific
ods known in the field of nuclear medicine including the methods for preparing protein microspheres.
sodium iodide method, germanium method or other
The protein microspheres of the invention have a
known methods of gamma ray detection. Re-186 and diameter of less than about 100 microns, preferably
Re-188 decay by /3-emission which provides the lethal 50 between about 3 and about 50 microns, more preferably
dose necessary for radiotherapy. Re-186 decays into a between about 5 and about 30 microns, and most prefer
stable daughter product and is characterized by a half- ably between about 10 and about 20 microns. As dis
life of about 90 hours, a strong /3-emission (1.07 MeV), cussed above, different sizes and size distributions of
and an essentially monoenergetic 137 keV imageable microspheres are desired for different applications. Re
gamma ray emission (9%). Re-188 decays into a stable 55 search is ongoing with respect to the relationship be
daughter product and is characterized by a half-life of tween microsphere size and efficacy for radiation ther
about 17 hours, a strong /3-emission (2.13 MeV), a 155 apy, as measured by, for example, containment within
keV imageable gamma-ray emission (15%).
the joint being treated. The density of the microspheres
Re-188 is preferred over Re-186 for certain applica is generally close to the density of water, preferably
tions such as radiation synovectomy because concerns 60 between about 1.0 and about 1.05 g/cc. The density is
relating to containment of radioactivity over time are such that the microspheres are readily suspendable in
not as great due to Re-188’s shorter half-life, i.e., the the carrier solution used for injection into the affected
time period during which Re-188 leakage is potentially joint of the host.
dangerous to the host is shorter. Additionally, Re-188’s
In accordance with one embodiment of the invention,
higher beta energy provides the necessary penetration 65 novel protein compositions have been devised for use as
to treat large joints such as the human knee. Re-188 is radioactivity carriers in therapeutic, diagnostic and
also advantageously readily producible from a W- research applications of nuclear medicine. One particu
188/Re-188 radioisotope generator analogous to known lar application for these compositions is the treatment of
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RA referred to hereinabove and as described in detail containing side chain to amino acid residues having
hereinbelow. These novel compositions, however, are nitrogen-containing side chains be in the range of about
adaptable for other radiotherapeutic and diagnostic 1:1 to about 1:3.
It is believed that the particular amino acid or amino
applications in mammals where radioactivity carriers
may be used including, for example, liver, lung and 5 acids selected for the amino acid residues having a ni
trogen-containing side chain is not critical, but the pre
kidney cancer treatment and lung scanning.
amino
acid
is
lysine
The compositions of the invention comprise proteins ferred
which have a predetermined minimum proportion, [NH2(CH2)4CH(NH2)COOH]. One preferred composi
about 6%, of amino acid residues having sulfhydryl- tion contains a combined cysteine and amino acid hav
containing side chains. The preferred amino acid having 10 ing a nitrogen-containing side chain content which ap
a sulfhydryl-containing side chain is cysteine proaches 100%. The most preferable of such composi
[HSCH2CH(NH2)]. A major advantage of these com tions contains about 50% cysteine and about 50% ly
positions is that their composition facilitates attachment sine. Other amino acids having nitrogen-containing side
of radioisotopes. Without being bound to any one the chains are substitutable in whole or in part for lysine in
ory, it is suspected that Re-186 and Re-188 radionu 15 the compositions. These amino acids include, nonclides, in particular, bind to protein compositions pri exclusively, arginine, asparagine, glutamine, histidine
marily at sulfhydryl-containing side chains, as are pres and tryptophan.
Though protein compositions of the invention are
ent in cysteine. The sulfhydryl-containing side chain of
cysteine is not involved in the internal peptide bond, preferably formed primarily from cysteine or cysteine
and, being located at one end of the amino acid, is avail 20 in combination with an amino acid having a nitrogenable for the formation of external bonds. A high concen containing side chain such as lysine, the compositions
tration of available sulfhydryl-containing side chains on may also contain certain proportions of other amino
the composition surface, therefore, is thought to favor acids or combinations thereof, depending on the partic
labeling efficiency and stability of the bond between the ular application, availability of material, and other fac
25 tors. The function of amino acids other than those hav
radioisotope and the composition.
HSA which, as indicated above, has been previously ing sulfhydryl- or nitrogen-containing side chains, as
proposed for use in radioactivity carriers for certain currently understood, is primarily to provide mass to
applications, has about 35 cysteine amino acid residues the compositions. In addition to lysine and cysteine,
out of a total of about 585 amino acid, residues accord appropriate amino acids for use in connection with
ing to Minghetti et al., Molecular Structure of Human 30 these compositions may be selected from the group
Albumin Gene Is Revealed by Nucleotide Sequence within which includes, non-exclusively, alanine, arginine, as
^11-22 of Chromosome 4, J. Biol. Chem., Vol. 261, No. paragine, aspartic acid, glutamine, glutamic acid, gly
15, p. 6753 (1986). Compositions formed substantially cine, histidine, isoleucine, leucine, methionine, phenyl
entirely from HSA, therefore, contain less than about alanine, proline, serine, threonine, tryptophan, tyrosine
6% cysteine. It has been discovered that compositions 35 and valine. As stated above, certain of these amino acids
having an increased content of amino acid residues have nitrogen-containing side chains and therefore may
having a sulfhydryl-containing side chain, such as cyste be included in the preferred compositions of the inven
ine relative to HSA have certain advantages as de tion. Certain amino acids are appropriate for use in the
scribed herein. The compositions of the invention con compositions of the invention, irrespective of whether
tain at least 6% amino acid residues having a sulfhydryl- 40 they have sulfhydryl-containing or nitrogen-containing
containing side chain, preferably at least about 10% side chains, so long as they are metabolizable, non-toxic,
amino acid residues having a sulfhydryl-containing side non-antigenic, and otherwise compatible with composi
chain, more preferably at least about 25% amino acid tions for use as in vivo radioactivity carriers.
The compositions comprise combinations of amino
residues having a sulfhydryl-containing side chain, and
most preferably at least about 35% amino acid residues 45 acids which are independent amino acid chains crosslinked, for example cysteine or polycysteine crosshaving a sulfhydryl-containing side chain.
It is also believed that the presence of amino acid linked to lysine or polylysine, upon formation of the
residues characterized by nitrogen-containing side composition. The compositions may also comprise
chains may favor labeling efficiency and stability of the polyamino acid chains having different amino acids in
bond between the radioisotope and the composition. 50 the same chain, as with a polyamino acid chain of ten
The beneficial effect of nitrogen-containing side chains amino acids, five lysines and five cysteines. Polyamino
is believed to involve interaction among die nitrogen- acids used in connection with the invention may be of a
containing side chains, sulfhydryl-containing side predetermined sequence.
The molecular weight of polyamino acid chains used
chains and radionuclides, or at least to otherwise pro
mote the desired binding between the composition and 55 in forming the compositions of the invention is in the
the radionuclides. Compositions of the invention there range of about 1000 to about 50,000 grams per mole,
fore preferably, but not necessarily, contain a propor preferably in the range of about 10,000 to about 20,000
tion of amino acid residues having nitrogen-containing grams per mole. Polyamino acid chains for these com
side chains in addition to the amino acid residues having positions have in the range of about 10 to about 400
sulfhydryl-containing side chains as described above. It 60 amino acids per chain, preferably in the range of about
is also preferred that the compositions of the invention 50 to about 200 amino acids per chain, and most prefera
contain at least about 10% amino acid residues having bly about 100 amino acids per chain. Chains which are
nitrogen-containing side chains, preferably at least too long or have too high of a molecular weight are
about 25% amino acid residues having nitrogen-con difficult to dissolve during the formation of the compo
taining side chains, and more preferably at least about 65 sitions. The protein material used to form the composi
35% amino acid residues having nitrogen-containing tions may be prepared any of various known or herein
side chains. For these compositions, it is preferred that after developed methods including chemical synthesis
the ratio of amino acid residues having a sulfhydryl- and microbial manufacture.
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Increased radionuclide-to-carrier bond strength and y3-mercaptoethanol (98% 2-hydroxyethyl-mercaptan
stability provided by the above-described compositions available from Sigma Chemical Co.) and DTT (99%
render the compositions less susceptible than other radi DL-dithiothreitol available from Sigma Chemical Co.).
oactivity carriers to enzymatic attack in the body and The reducing agent is provided in a concentration in the
therefore less susceptible to in vivo leaching of radioac 5 range of from about 0.2 to about 10%, preferably in the
tivity into the host’s system. For example, the strong range of from about 0.5 to about 5%, and most prefera
Re-to-sulfhydryl and/or Re-to-amine bond thought to bly in the range of from about 0.5 to about 2%. The
be characteristic of Re-radiolabeled cysteine/lysine compositions are suspended in the reducing agent solu
compositions may reduce the tendency of Re to be tion and heated in a boiling water bath for about 30 to
oxidized in vivo to perrhenate. Compositions formed 10 about 90 minutes.
primarily from lysine, cysteine and/or other suitable
Protein compositions for use in connection with the
amino acids are preferred over HSA due to the forego method of the invention can be radiolabeled directly.
ing advantages and due to immunogenetic and infec By direct labeling, Re-186 or Re-188 is reduced from
tion-related concerns with using blood products such as the VII oxidation state to the V oxidation state and
human albumin.
15 bound directly to connecting groups on the composi
The amino acid or combination of amino acids se tions. Without being bound to any one theory, radioac
lected for the compositions are preferably metaboliz tive oxo Re(V), reduced from perrhenate, is believed to
able, non-toxic, and non-antigenic. The L isomer of the form a stable complex (transfer ligand) which is readily
selected amino acid is preferred over the D isomer attachable to thiol and amine groups on protein mole
because the L conformations are naturally occurring. 20 cules. This preferred labeling method and the presumed
Naturally occurring isomers may be more compatible mechanism are further described in FIG. 1. Each milli
with the host, readily metabolizable, and, being indige gram of the protein compositions can be labeled with up
nous to mammals, more readily approved for use in to about 1 to about 4 millicuries Re, but generally is
mammals by governmental authorities. It is also pre labeled with about 50 to about 500 microcuries Re,
ferred that the amino acid or combination of amino 25 preferably with about 100 to about 400 microcuries Re,
acids, when formed and solidified into a composition, be and most preferably with about 100 to about 300 mi
sufficiently chemically durable in vivo such that signifi crocuries Re. Specifically, a transfer ligand is obtained
cantly harmful amounts of radioactivity are not leached by combining a Re reducing agent such as tin (II) chlo
from radiolabeled compositions formed therefrom into ride 99%, a Re stabilizing agent such as citric acid and
the host’s system during a period of about five half-lives 30 an antioxidant such as gentisic acid in a reaction vial.
of the attached radioisotope.
The vial is purged with nitrogen gas and deoxygenized,
The preparation of the preferred protein composi deionized water is added to form a solution having a pH
tions, when formed into microspheres, can be achieved of about 3. The desired amount of radioactive perrhe
by the emulsification method, the drop-tube method, or nate (comprising Re-186 or Re-188), generally about 50
other suitable methods as is the case with HSA micro- 35 to about 500 microcuries per milligram of composition
spheres. Although the method by which the micro to be labeled, is transferred into the reaction vial and
spheres are made is not critical to the invention, the reduced upon heating for about 30 minutes in a boiling
emulsification method as described herein.
water bath. The Re(V) citrate complex solution is then
It has been discovered that extensive washing and transferred into a glass tube containing agitated protein
pretreatment of the compositions, both HSA composi 40 composition suspension. The glass tube is placed into a
tions and other protein compositions, significantly im boiling water bath; stirring and heating are maintained
prove the chemical durability and overall labelability of for about 1 hour. The Re-labeled compositions are then
the compositions. Washing the compositions thor separated from the aqueous supernatant
oughly with saline and a detergent is thought to remove
Radiolabeling may also be accomplished in accor
loosely bound protein molecules. It is most preferred 45 dance with the method and mechanism wherein a stable
that the detergent be a non-ionic detergent, specifically, Re complex is formed and then attached to the compo
sodium dodecyl sulfate, but other detergents are suit sition as set forth in FIG. 2.
able. Chemical durability in vivo is improved in that
Radiolabeled protein compositions produced as de
loosely bound proteins are removed and therefore not scribed above may be used in connection with the
available to be released, i.e., leached, within the host’s 50 method of the invention for radiation synovectomy
system.
treatment of RA. In accordance with the method of the
Treatment of the compositions with a reducing agent invention, radiolabeled microspheres prepared as de
has been found to significantly improve the efficacy of scribed are administered to afflicted joints of a mammal
the compositions for attachment of radionuclides and by intra-articular injection or other suitable means of
subsequent use for nuclear medical applications. Pre 55 administration. The dosage for treatment of an afflicted
treatment of the compositions in this manner reduces in joint depends on various factors including the size of the
vivo leakage of the radionuclides. Without being bound joint, the progression of the disease, and the tolerance of
to any one theory, it is suspected that this treatment the patient. The typical dosage is in the range of from
serves to reduce disulfide bonds, formed from sulfhy- about 0.5 to about 20 milligrams of microspheres radi
dryl groups upon heating of the compositions during 60 olabeled with about 50 to about 500 microcuries Re per
preparation, back to sulfhydryl groups. This reduction milligram. Upon administration, the microspheres be
is believed to substantially increase the number of avail come distributed reasonably uniformly along the syno
able bonding sites for attachment of radioisotopes to the vial membrane and emit beta radiation of sufficient
compositions. In particular, it is believed that this pre- strength to fully irradiate the thickness of the membrane
treatment facilitates the reformation of sulfhydryl 65 without imparting significant dosage to more distant
groups having affinity for the radiolabel to be attached joint structures. Inasmuch as the thickness of the dis
(Re(V)). Reducing agents capable of this type of reduc eased membrane varies in different joints, the present
tion are well known in the art, including, for example, invention makes possible the injection of different size
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microspheres for a knee than for a finger joint, for ex posable hypodermic syringe using a 25-gauge needle.
The polypeptide was a 50:50 molar mixture of cysteine
ample.
The following examples illustrate certain preferred and lysine. The oil/polypeptide mixture was heated to
embodiments of this method and the efficacy of the about 120° C. and maintained at that temperature for
compositions of the invention for radiation therapy, 5 about 60 minutes while stirring was continued. The oil
including treatment, diagnosis and research, in mam suspension was cooled to room temperature and the
mals. The protocol and experimental methods followed microspheres were isolated by centrifugation. After
were approved by the University of Missouri-Columbia several washes with heptane and acetone to completely
Animal Care and Use Committee and complied with the remove the oil, the microspheres were dried with nitro
10 gen gas.
federal Animal Welfare Act.
About 15-20 mg of protein microspheres were placed
EXAMPLE 1
with
a magnetic stir bar into a 10 ml glass tube for preHSA microspheres acceptable for use in connection
Five ml of 1-1.5% /3-mercaptoethanol (98%
with the method of the invention were produced by treatment.
2-hydroxyethylmercaptan
available from Sigma Chemi
placing 200-300 ml of cottonseed oil (USP) in a glass 15 cal Co.) and 1 ml of 1% Tween-80
polyoxoethybeaker and stirring at about 500 rpm with a 2\ inch lene sorbitan monooleate available (liquid
from
Sigma
Chemi
propeller-type stirrer. An aqueous solution of 25%
HSA at ambient temperature was added to the beaker cal Co.) were added to the tube. 0.5-1.0% DTT (99%
using a hypodermic syringe with a 25-gauge needle. /ji-dithiothreitol available from Sigma Chemical Co.)
HSA was added at a volume ratio of 4 ml per liter of oil. 20 may be substituted for the /3-mercaptoethanol. The
The oil/HSA mixture was heated to 135° C. and main microsphere suspension was heated in a boiling water
tained at that temperature for about 40 minutes while bath and stirred for 45-60 minutes. The supernatant was
stirring was continued. The oil suspension was cooled removed by centrifugation and the microspheres were
to room temperature, diluted with heptane, and the washed with deionized water and allowed to dry.
microspheres were isolated by filtration. After several 25 Transfer ligand was obtained by placing about 6 mg
washes with heptane to completely remove the oil, the tin (II) chloride 99%, about 55 mg citric acid, about 50
microspheres were dried.
mg sodium citrate, and about 20 mg gentisic acid in a 5
About 15-20 mg of protein microspheres were placed ml reaction vial. The vial was purged with nitrogen gas
with a magnetic stir bar into a 10 ml glass tube for pre and 1.5 ml of previously deoxygenized, deionized water
treatment. Five ml of 1-1.5% /3-mercaptoethanol (98% 30 was added to form a solution of about pH 3. About 1 to
2-hydroxyethyl-mercaptan available from Sigma Chem 1.5 ml radioactive perrhenate containing about 5 milliical Co.) and 1 ml of 1% Tween-80 (liquid polyoxoethy- curies
high specific, activity Re-186 (about 1 to.3
lene sorbitan monooleate available from Sigma Chemi curies of
per
milligram) or generator-produced Re-188
cal Co.) were added to the tube. 0.5-1.0% DTT (99% was transferred
into the reaction vial containing trans
DL-dithiothreitol available from Sigma Chemical Co.) 35 fer ligand and reduced
upon heating for about 30 min
may be substituted for the /3-mercaptoethanol. The utes in a boiling water bath.
The Re(V) citrate complex
microsphere suspension was heated in a boiling water solution was promptly transferred
a glass tube con
bath and stirred for 45-60 minutes. The supernatant was taining a micro-stirrer and 1 ml into
protein microsphere
removed by centrifugation and the microspheres were
40 suspension in 0.5% Tween-80 containing 15 mg microwashed with deionized water and allowed to dry.
Transfer ligand was obtained by placing about 6 mg spheres. The glass tube was placed into a boiling water
tin (II) chloride 99%, about 55 mg citric acid, about 50 bath; stirring and heating were maintained for about 1
mg sodium citrate, and about 20 mg gentisic acid in a 5 hour. The Re-labeled microspheres were separated
ml reaction vial. The vial was purged with nitrogen gas from the aqueous supernatant through centrifugation
and 1.5 ml of previously deoxygenized, deionized water 45 and thoroughly washed with deionized water or iso
was added to form a solution of about pH 3. About 1 to tonic saline.
1.5 ml radioactive perrhenate containing about 5 milliEXAMPLES 3-6
curies of high specific activity Re-186 (about 1 to 3
curies per milligram) or generator-produced Re-188
Microspheres containing about 50% polylysine and
was transferred into the reaction vial containing trans 50 about 50% polycysteine by mole percent were prepared
fer ligand and reduced upon heating for about 30 min and directly labeled with Re-186 as described above in
utes in a boiling water bath. The Re(V) citrate complex Example 2. Each microsphere had a diameter between
solution was promptly transferred into a glass tube con about 6 and about 80 microns, with about 50% of the
taining a micro-stirrer and 1 ml protein microsphere microspheres having a diameter between about 10 and
suspension in 0.5% Tween-80 containing 15 mg micro- 55 about 40 microns. 1-2 mg microspheres suspended in
spheres. The glass tube was placed into a boiling water saline solution carrying about 200-400 microcuries
bath; stirring and heating were maintained for about 1 were injected, using 1 ml tuberculin syringes, into the
hour. The Re-labeled microspheres were separated rear knee joint (stifle) of each of four New Zealand
from the aqueous supernatant through centrifugation white rabbits. The radioactivity in the urine of each
and thoroughly washed with deionized water or iso 60 rabbit as measured daily for four days is presented in
tonic saline.
FIG. 3. Each rabbit was sacrificed after four days and
EXAMPLE 2
the data presented in FIGS. 4-5 collected. These data
Polycysteine-polylysine microspheres were pro reveal that the percent injected dose remaining in the
duced by placing 200 ml of mineral oil (USP) in a 500 ml 65 stifle after 96 hours was as high as 87%, the percent
glass beaker, stirring with a magnetic stir bar and heat injected dose in the urine averaged about 11%, and the
ing the oil to about 65° C. A 3 ml solution of polypep percent injected dose remaining in the tissue was as low
tide in dichloroacetic acid was added from a 3 ml dis as about 0.08%.
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4. The composition of claim 2, said composition fur
EXAMPLE 7
ther comprising at least about 25 molar percent amino
5 mg 50% polylysine and 50% polycysteine micro acid residues having a nitrogen-containing side chain.
spheres prepared as in Example 2 were placed in saline
5. The composition of claim 1 wherein said beta radi
solution at 37° C. The percent radioactivity leached 5 ation emitting radioisotope is Re-186, Re-188, or a com
after each of four days was determined and is reported bination of Re-186 and Re-188.
in FIG. 6. Less than 0.03% of the Re label leached in 96
6. The composition of claim 1 wherein said composi
hours.
tion is a substantially spherical microsphere.
7. A radiolabeled protein microsphere adapted for
EXAMPLE 8
10 radiation therapy of a mammal comprising a substan
Re-186 labeled HSA microspheres prepared accord
spherical microsphere comprising a protein com
ing to the method of Example 1, except that they were tially
position
radioisotope selected from the group
not pretreated with /J-mercaptoethanol or DTT, and consistingandof aRe-186,
and the combination of
having a range of diameter from 1 to 50 microns, were Re-186 and Re-188, saidRe-188,
microsphere
suspended in isotonic saline solution and injected into 15 between 10 microns and 30 microns. having a diameter
the rear stifles of each of four New Zealand white rab
8. The microsphere of claim 7 wherein the micro
bits using 200 microliter glass syringes. Each rabbit was sphere
at least about 25 molar percent cyste
sacrificed after 24 hours and the data presented in FIG. ine andcomprises
at least about 25 molar percent amino acid resi
7 collected. In a second in vivo study using micro- dues having
a nitrogen-containing side chain.
spheres which had not undergone pretreatment, leakage 20 9. The microsphere
of claim 8 wherein said cysteine
to the urine was significantly higher, about 30%, after 4 and said amino acid residues
having a nitrogen-contain
days.
ing side chain combine to form about 100% of the mi
crosphere.
EXAMPLE 9
spherical radiolabeled protein
Re-186 labeled HSA microspheres were prepared 25 10. A substantially
adapted for radiation therapy of a mammal
and injected as set forth in Example 8, except that the microsphere
a substantially spherical microsphere com
microspheres were suspended in Angiovist instead of comprising
at least about 35 molar percent lysine and at least
isotonic saline solution. Each rabbit was sacrificed after prising
about 35 molar percent cysteine and a radioisotope
24 hours and the data presented in FIG. 7 collected.
30 selected from the group consisting of Re-186, Re-188,
EXAMPLE 10
and the combination of Re-186 and Re-188.
11. A radiolabeled protein composition adapted for
Re-186 labeled HSA microspheres were prepared
and injected as set forth in Example 9, except that only radiation therapy or diagnosis of a mammal comprising
microspheres having diameters of approximately 23 a beta radiation emitting radioisotope and a protein
microns were used. Each rabbit was sacrificed after 24 35 composition comprising at least 6 molar percent cyste
hours and the data presented in FIG. 7 collected. The ine, said composition being sufficiently chemically du
mean percent dose of radioactivity distributed at 24 rable in vivo such that significantly harmful amounts of
hours in certain rabbit organs for Examples 8-10 was radioactivity are not leached from the composition into
a host’s system during a period of about five half-lives of
determined and is presented in FIG. 8.
In view of the above, it will be seen that the several 40 the attached radioisotope when the composition is in
jected into the host’s system.
objects of the invention are achieved.
12. The composition of claim 11 comprising at least
Although specific examples of the present invention
and its application are set forth herein, it is not intended about 10 molar percent cysteine and at least about 10
that they are exhaustive or limiting of the invention. molar percent amino acid residues having a nitrogenThese illustrations and explanations are intended to 45 containing side chain.
13. The composition of claim 11 wherein said beta
acquaint others skilled in the art with the invention, its
principles, and its practical application, so that others radiation emitting radioisotope is Re-186, Re-188, or a
skilled in the art may adapt and apply the invention in combination of Re-186 and Re-188.
14. The composition of claim 11 wherein said compo
its numerous forms, as may be best suited to the require
ments of a particular use.
50 sition is a substantially spherical microsphere.
We claim:
15. The microsphere of claim 7 which is sufficiently
1. A radiolabeled protein composition adapted for chemically durable in vivo such that significantly harm
radiation therapy or diagnosis of a mammal, comprising ful amounts of radioactivity are not leached from the
a beta radiation emitting radioisotope and a protein composition into a host’s system during a period of
composition comprising at least 10 molar percent amino 55 about five half-lives of the attached radioisotope when
acid residues having a sulfhydryl-containing side chain, the composition is injected into the host’s system.
said composition being sufficiently chemically durable
16. A radiolabeled protein composition adapted for
in vivo such that significantly harmful amounts of radio radiation therapy of a mammal comprising a beta radia
activity are not leached from the composition into a tion emitting radioisotope and a protein composition
host’s system during a period of about five half-lives of 60 comprising at least 10 molar percent amino acid resi
the attached radioisotope when the composition is in dues having a sulfhydryl-containing side chain, said
jected into the host’s system.
composition being a solidified protein composition
2. The composition of claim 1, said composition com which is suspended in a carrier solution for injection
prising at least about 25 molar percent amino acid resi and administration by distribution of the solidified com
dues having a sulfhydryl-containing side chain.
65 position to an area of a host to receive radiation therapy.
3. The composition of claim 2, said composition com
17. The composition of claim 11, said composition
prising at least about 35 molar percent amino acid resi comprising at least about 25 molar percent amino acid
dues having a sulfhydryl-containing side chain.
residues having a sulfhydryl-containing side chain.
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22. A radiolabeled protein microsphere adapted for
18. The composition of claim 17 wherein said beta
radiation emitting radioisotope is Re-186, Re-188, or a radiation therapy of a mammal comprising a spherical
protein microsphere consisting of 50 molar percent
combination of Re-186 and Re-188.
and 50 molar percent polycysteine, said po19. The composition of claim 16 wherein said compo 5 polylysine
lylysine
and
said polycysteine being polyamino acid
sition is a substantially spherical microsphere.
chains
consisting
of between about 10 and about 400
20. The composition of claim 16 having a density amino acid residues
per chain, and a radioisotope at
between about 1.0 and about 1.05 g/cc.
tached
to
said
microsphere
from the group
21. The composition of claim 4 wherein the ratio of consisting of Re-186, Re-188,selected
and the combination of
amino acid residues having a sulfhydryl-containing side 10 Re-186 and Re-188, said microsphere having a diameter
chain to amino acid residues having a nitrogen-contain between about 6 microns and about 80 microns.
* * * * *
ing side chain is in the range of 1:1 to 3:1.
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